Paperpal Prime Logo

Journal of Child and Adolescent Psychopharmacology : Impact Factor & More

eISSN: 1557-8992pISSN: 1044-5463

Key Metrics

CiteScore
4.1
H-Index
90
Impact Factor
< 5
SJR
Q1Pharmacology (medical)
SNIP
1.02
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Journal of Child and Adolescent Psychopharmacology

Journal of Child and Adolescent Psychopharmacology Journal Specifications

Overview
Publisher MARY ANN LIEBERT, INC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1990
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Journal of Child and Adolescent Psychopharmacology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Journal of Child and Adolescent Psychopharmacology

Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.
  • 1 Sep 2026
  • Journal of child and adolescent psychopharmacology
Letter: Restricted Access to Electroconvulsive Therapy in Pediatric and Adolescent Patients-Clinical and Familial Consequences: Case Report.
  • 8 Aug 2026
  • Journal of child and adolescent psychopharmacology
Amantadine-Responsive, Benzodiazepine-Resistant Catatonia in an Adolescent With Autism Spectrum Disorder.
  • 7 Aug 2026
  • Journal of child and adolescent psychopharmacology
Letter: Elevated Prolactin as a Potential Clinical Clue for Sensitivity to D2 Antagonism in an Adolescent Female Presenting with Recurrent Oculogyric Crises--A Case Study.
  • 7 Aug 2026
  • Journal of child and adolescent psychopharmacology
A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.
  • 1 Aug 2026
  • Journal of child and adolescent psychopharmacology
Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome.
  • 1 Aug 2026
  • Journal of child and adolescent psychopharmacology
Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.
  • 1 Sep 2026
  • Journal of child and adolescent psychopharmacology
Letter: Restricted Access to Electroconvulsive Therapy in Pediatric and Adolescent Patients-Clinical and Familial Consequences: Case Report.
  • 8 Aug 2026
  • Journal of child and adolescent psychopharmacology
Amantadine-Responsive, Benzodiazepine-Resistant Catatonia in an Adolescent With Autism Spectrum Disorder.
  • 7 Aug 2026
  • Journal of child and adolescent psychopharmacology
Letter: Elevated Prolactin as a Potential Clinical Clue for Sensitivity to D2 Antagonism in an Adolescent Female Presenting with Recurrent Oculogyric Crises--A Case Study.
  • 7 Aug 2026
  • Journal of child and adolescent psychopharmacology
A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.
  • 1 Aug 2026
  • Journal of child and adolescent psychopharmacology
Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome.
  • 1 Aug 2026
  • Journal of child and adolescent psychopharmacology

FAQs on Journal of Child and Adolescent Psychopharmacology